Pulmoven Duo

PULMOVEN DUO
Bronchodilator . Mucolytic . Fluidizing.

The respiratory tract diseases are professional diseases of the equine because of its sport activity primarily for being housed for almost 23 hours per day, with they have to live frequently.
The presence of mucus and bronchial spasms are common features of these states .
Up to now, it did not exist in the argentinian veterinary market a simultaneous formulation to treat respiratory diseases with signs of mucus and bronchospasm .
Sport Horse  achieve to  formulate Pulmoven Duo, an effective therapeutic weapon , usefull and economic, recovering, this way, the respiratory capacity and deportive attitude.


Pulmoven Duo is indicated for respiratory diseases that present with bronchospasm presence of mucus and / or mucopurulent such as bronchopneumonia , laryngeal tracheitis , bronchitis different evolution (acute , subacute or chronic) , bronchiolitis , COPD ( chronic obstructive pulmonary disease) , atelectasis. Sinusitis .
Can also be used as adjuvant in treatment of respiratory tract infections .
Supportive therapy in allergic for housing , suspended particles , chip beds , etc. .
Viscosity decrease tracheobronchial mucosa.

Use in Veterinary Medicine
Net Cont : 500 ml
Ready to use

Formula:
Each 100 ml contains :
N-Acetylcysteine ...................................... 20,000 g
Clenbuterol .............................................. 0,002 g
FormulatiON agents q.s..............................100 ml

Target species : Equine sports exclusively .

Routes of application :
Apply orally with syringe.
Insert the syringe into the bottle, invert it upside down and letting it load the syringe by pulling the plunger until you reach the desired dosage
Dosage: 4 g per 100 kg .
For acute or subacute : Administer every 12 hours for 10-14 days or until remission
of symptoms.
For chronic cases : Administer every 12 hours and can extend up to 28 days
treatment .

The dosage is up to the acting professional , who will assess the state of the 
animal in each case.